Wang Yue-Ting, Price Edward, Feng Mei, Hulen Jason, Doktor Stella, Stresser David M, Maes Estelle M, Ji Qin C, Jenkins Gary J
Quantitative, Translational, and ADME Sciences (QTAS), AbbVie Inc., North Chicago, Illinois 60064, United States.
J Med Chem. 2024 Aug 22;67(16):13765-13777. doi: 10.1021/acs.jmedchem.4c00571. Epub 2024 Jul 8.
Permeability is a key factor driving the absorption of orally administered drugs. In early discovery, the efficient evaluation of permeability, particularly for compounds violating Lipinski's Rule of 5, remains challenging. Addressing this, we established a high-throughput method to measure the experimental polar surface area (HT-EPSA) as an in vitro surrogate to measure permeability. Compared to earlier methods, HT-EPSA significantly reduces data acquisition time with enhanced sensitivity, selectivity, and data quality. In the effort of translating EPSA to human in vitro and in vivo passive permeability, we demonstrated the application of EPSA for predicting Caco-2 cell and human intestinal permeability, showing improvements over topological polar surface area and the parallel artificial membrane permeability assay for rank-ordering permeability in a proteolysis targeting chimera case study. The HT-EPSA method is expected to be highly beneficial in guiding early stage compound rank-ordering, faster decision-making, and in predicting in vitro and/or in vivo human intestinal permeability.
通透性是驱动口服药物吸收的关键因素。在早期发现阶段,对通透性进行有效评估,尤其是对于违反Lipinski五规则的化合物,仍然具有挑战性。为了解决这个问题,我们建立了一种高通量方法来测量实验性极性表面积(HT-EPSA),作为测量通透性的体外替代指标。与早期方法相比,HT-EPSA显著减少了数据采集时间,同时提高了灵敏度、选择性和数据质量。在将EPSA转化为人体体外和体内被动通透性的过程中,我们证明了EPSA在预测Caco-2细胞和人体肠道通透性方面的应用,在一个蛋白酶靶向嵌合体案例研究中,与拓扑极性表面积和平行人工膜通透性测定相比,在通透性排序方面有改进。HT-EPSA方法有望在指导早期化合物排序、加快决策以及预测体外和/或体内人体肠道通透性方面非常有益。